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Abstract
Background: Preserved ratio impaired spirometry (PRISm) is an incompletely understood respiratory condition. We
investigated the incidence and significant predictive factors of chronic obstructive pulmonary disease (COPD) in
PRISm patients.
Methods: From 11,922 subjects registered in the Korea National Health and Nutrition Examination Survey, never or
light smokers, young subjects, and those already medically diagnosed with COPD (defined by ICD-10 code and
prescribed medication) were excluded. The 2666 remaining subjects were categorized into PRISm (normal forced
expiratory volume in the first second [FEV1]/force vital capacity [FVC] [≥ 0.7] and low FEV1 (< 80%); n = 313); normal
(n = 1666); and unrevealed COPD groups (FEV1/FVC ratio < 0.7; n = 687). These groups were compared using
matched Health Insurance Review and Assessment Service data over a 3-year follow-up.
Results: COPD incidence in PRISm patients (17/1000 person-year [PY]) was higher than that in normal subjects (4.3/
1000 PY; P < 0.001), but lower than that in unrevealed COPD patients (45/1000 PY; P < 0.001). PRISm patients visited
hospitals, took COPD medication, and incurred hospitalization costs more frequently than normal subjects, but less
frequently than unrevealed COPD patients. In the overall sample, age, FVC, FEV1, dyspnea, and wheezing were significant
predictors of COPD, but in PRISm patients, only age (OR, 1.14; P = 0.002) and wheezing (OR, 4.56; P = 0.04) were significant
predictors.
Conclusion: PRISm patients are likely to develop COPD, and should be monitored carefully, especially older patients and
those with wheezing, regardless of lung function.
Keywords: Chronic obstructive pulmonary disorder, Prognosis, Spirometry
Background
Despite the escalating prevalence and economic burden of
chronic obstructive pulmonary disease (COPD), many
COPD cases remain undiagnosed worldwide [1–3]. A lack
of awareness of COPD, lack of educational programs con-
cerning COPD, poor physician adherence to guidelines,
and low usage of pulmonary function tests leads to under-
diagnosis of COPD [4, 5]. Many studies have reported that
patients with early COPD or even pre-COPD (e.g.,
smokers or subjects with impaired lung function) have
respiratory symptoms and utilize medical support [6, 7].
This has emphasized early-diagnosis and early-treatment
of COPD. However, subjects with preserved ratio impaired
spirometry (PRISm) are often missed. PRISm patients do
not meet COPD criteria [8], with a preserved ratio of force
expiratory volume in the first second [FEV1]/forced vital
capacity [FVC] (> 0.7), but have reduced FEV1 (< 80%,
predicted), yet exhibit increased respiratory symptoms,
decreased activity, increased comorbidity, and increased
mortality [7, 9–14]. Wan et al. described PRISm as a
COPD subtype with increased emphysema and gas
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trapping [15]. Lung density on computed tomography is
significantly associated with lung function in PRISm [16].
Thus, some aspects of PRISm are associated with COPD
development with worsening of lung function; but the
COPD incidence in PRISm patients has rarely been
reported.
Tobacco smoking, ageing, air pollution, poor nutritional
status, impaired lung function, and underlying asthma are
established risk factors for COPD [17, 18]. However, the
risk factors associated with COPD in PRISm remain un-
known. We sought to elucidate the incidence of COPD in
PRISm patients and to identify the significant risk factors
for COPD in PRISm, using Korean national cohort data.
Methods
Subjects and study design
We used the cross-sectional the Korea National Health
and Nutrition Examination Survey (KNHANES) data of
2007–2009 and KNHANES-matched Health Insurance Re-
view and Assessment (HIRA) cohort data of 2006–2012. A
total of 11,922 subjects were available in KNHANES.
Among them, never- or light-smokers (< 10 pack-years),
young subjects (< 40 years), and patients already medically
diagnosed with COPD (based on the ICD-10 code and pre-
scribed medication in HIRA), were excluded (n = 9256).
We categorized the remaining 2666 subjects into 3 groups
based on spirometry (Fig. 1). The normal group (n = 1666)
had a normal FEV1/FVC ratio (≥ 0.7) and normal spirom-
etry (FEV1 ≥ 80% predicted). PRISm subjects (n = 313) had
a normal FEV1/FVC ratio (≥ 0.7) and decreased lung
function (FEV1 < 80% predicted). Unrevealed COPD sub-
jects had a decreased FEV1/FVC ratio (< 0.7), regardless of
FEV1 and FVC. KNHANES data did not include
post-bronchodilator FEV1 and FVC, which are recom-
mended in the guidelines [8, 19]; we therefore used
pre-bronchodilator FEV1 and FVC values.
KNHANES and HIRA data
KNHANES data were derived from a national large-scale
cross-sectional survey conducted by the Korean govern-
ment, via the Korea Centers for Disease Control and
Prevention. This data were obtained from a well-designed
national program with complex, multistage probability
sample extraction to reflect the total population of Korea.
KNHANES data include age, sex, height, weight,
self-reported smoking history, self-reported co-morbidity
(answers to the following questions: do you have [the
disease, e.g., asthma] diagnosed by a doctor?), results of
spirometry tests obtained using Korean classic guidelines
[20], and self-reported respiratory symptoms (answers to
the following questions: do you have [symptom, e.g., cough
for 3 months]?). We enrolled subjects based on age, smok-
ing history (in pack-years, PY), and lung function in the
KNHANES data. Other baseline characteristics were also
obtained from the KNHANES data.
Subjects enrolled in the KNHANES database have
KNHANES-matched HIRA data. HIRA data were obtained
from claims from the national health insurance system,
which uniquely covers virtually all residents in Korea. It
contains the diagnostic code, medical utilization (including
Fig. 1 Subject selection and group assignment based on the KNHANES and HIRA data. KNHANES, Korea National Health and Nutrition
Examination Survey; HIRA, Health Insurance Review & Assessment; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume
for 1 s; FVC, forced vital capacity
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hospital admission history and prescribed medication), and
costs for several years [21].
Parameter definition
Contrary to the established spirometry-based diagnostic
criterion for COPD (FEV1/FVC < 0.7), “medically diagnosed
COPD” was defined by diagnostic code and prescribed
medication [22, 23]. Medically diagnosed COPD patients
met all of the following criteria: 1) age ≥ 40 years; 2)
ICD-10 codes for COPD or emphysema (J43.0×-J44.x, with
the exception of J43.0 as primary or secondary [within
fourth position] diagnosis); and 3) the use of more than 1
of the following COPD medications at least twice per year:
long-acting muscarinic antagonist, long-acting beta-2 agon-
ist (LABA), fixed-dose inhaled corticosteroid with LABA,
short-acting muscarinic antagonist (SAMA), short-acting
beta-2 agonist (SABA), SAMA with SABA, phosphodiest
erase-4 (PDE-4) inhibitor, systemic beta agonist, or
methylxanthine.
Hospitalization cost was defined as any medical
utilization costs for inpatient services, confined to ad-
missions with an ICD-10 code for COPD (J43.x–J44.x,
except J430) or COPD-related diseases (pneumonia:
J12.x–J17.x; pulmonary thromboembolism: I26, I26.0,
and I26.9; dyspnea: R06.0; or acute respiratory distress
syndrome: J80). Costs were presented in US dollar
(USD), using an exchange rate of 1 USD = 1090 Korean
Won (exchange rate as on February 9, 2018).
Chronic bronchitis was defined as self-reported
chronic cough or sputum persisting for at least 3 months,
in at least 2 consecutive years.
Outcomes
We analyzed the 3-year follow-up outcomes from HIRA
data (Fig. 2). The incidence of medically diagnosed COPD
was the primary outcome. Hospital visits, number and
type of prescribed medication, and hospitalization cost
were secondary outcomes. Furthermore, we sought to
identify significant factors that predicted a COPD diagno-
sis by group.
Ethics
This study was approved by the Institutional Review
Board of Gangnam Severance Hospital (number: 3–
2017-0395). The requirement for obtaining informed
consent from the patients was waived due to the retro-
spective nature of this study.
Statistical analyses
We compared the baseline characteristics, COPD inci-
dence, hospital visits, medication use, and hospitalization
cost between groups using χ2 tests (categorized variables)
and analysis of variance with Bonferroni post-hoc test
(continuous variables). Univariate and multivariate logistic
regression analyses were conducted to identify factors that
predicted COPD diagnosis. In multivariate analysis, only
factors found significant in univariate analysis were in-
cluded as co-variables. FEV1/FVC was not used in multi-
variate analysis, because of increased multicollinearity
(variance inflation factor = 23.81). P < 0.05 was considered
to indicate statistical significance.
Results
Demographics of subjects by group
Unrevealed COPD subjects (64.48 ± 9.54 years) were sig-
nificantly older than subjects in the normal (54.57 ±
10.52 years; P < 0.001) and PRISm (55.97 ± 10.85 years; P <
0.001) groups. Most subjects were men, and the sex distri-
bution was similar among groups. Height and weight were
less in the unrevealed COPD than in the normal and
PRISm subjects. Smoking PY was heavier in the unrevealed
COPD group than in the normal and PRISm groups. How-
ever, PRISm subjects were more often current-smokers
(61.7%) than were normal (51.5%; P = 0.003) and unre-
vealed COPD (53.4%; P = 0.045) subjects. Hyperlipidemia
was less common in the unrevealed COPD (6.8%) than in
the normal group (10.0%; P = 0.048). Acute coronary
Fig. 2 Scheme of study and summary of data presentation. KNHANES, Korea National Health and Nutrition Examination Survey; HIRA, Health
Insurance Review & Assessment
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syndrome was more common in the unrevealed COPD
(2.3%) than in the normal (1.0%; P = 0.042) group. Dia-
betes mellitus was significantly more prevalent in PRISm
(20.1%) than in normal (10.4%; P < 0.001) and unrevealed
COPD (12.2%; P = 0.003) subjects. Pulmonary tuberculosis
and asthma was particularly prevalent in the unrevealed
COPD group (Table 1).
FVC was significantly lower in the PRISm (72.55 ±
9.45%) than in the normal (92.96 ± 10.02%; P < 0.001)
and unrevealed COPD (88.51 ± 15.02%; P < 0.001)
groups. FEV1 followed a similar pattern. However, the
FEV1/FVC ratio was significantly lower in the unre-
vealed COPD (0.61 ± 0.09) than in the normal (0.79 ±
0.05, P < 0.001) and PRISm (0.77 ± 0.06, P = 0.035)
groups. Wheezing was more prevalent in PRISm (11.8%)
patients than in normal subjects (7.0%; P = 0.009), but
less prevalent than in the unrevealed COPD group
(22.4%, P < 0.001). Other respiratory symptoms followed
a similar pattern (Table 1).
COPD incidence, medication and hospital utilization, and
cost
The COPD incidence in PRISm subjects (17.0/1000 per-
son year [PY]) was significantly higher than that in normal
subjects (4.4/1000 PY; P < 0.001); however, that in unre-
vealed COPD individuals (45.1/1000 PY) was significantly
higher than that in PRISm individuals (P < 0.001). The
PRISm group (13.1%) significantly more often visited the
hospital than the normal group (7.3%; P = 0.002), but less
often than the unrevealed COPD group (24.6%; P < 0.001).
The type and number of prescribed medications followed
a similar pattern. Hospitalization cost in the PRISm group
(398.61 ± 1975.51 USD) was almost double that in the
normal group (186.17 ± 1411.24 USD; P = 0.297); however,
Table 1 Demographics of subjects according to the group
Normal PRISm Unrevealed COPD P-value P-value* P-value+ P-value‡
Age 54.57 ± 10.52 55.97 ± 10.85 64.48 ± 9.54 < 0.001 0.083 < 0.001 < 0.001
Male, n (%) 1560 (93.6) 286 (91.4) 654 (95.2) 0.063 0.426 0.432 0.054
Height (cm) 167.14 ± 6.94 166.79 ± 6.94 165.97 ± 6.56 < 0.001 0.998 <.0.001 0.236
Weight (kg) 68.29 ± 9.91 68.66 ± 11.6 63.7 ± 9.8 < 0.001 0.998 < 0.001 < 0.001
Smoking history
Current smoking, n (%) 858 (51.5) 193 (61.7) 367 (53.4) 0.004 0.003 0.999 0.045
Pack-years 28.62 ± 17.11 33.20 ± 20.34 36.58 ± 21.14 < 0.001 < 0.001 < 0.001 0.026
Co-morbidity, n (%)
Hypertension 453 (27.2) 91 (29.1) 209 (30.4) 0.269 0.998 0.336 0.999
Hyperlipidemia 166 (10.0) 34 (10.9) 47 (6.8) 0.035 0.998 0.048 0.092
Stroke 48 (2.9) 14 (4.5) 18 (2.6) 0.252 0.414 0.999 0.368
Acute coronary syndrome 17 (1.0) 8 (2.6) 16 (2.3) 0.019 0.077 0.042 0.999
Diabetes mellitus 174 (10.4) 63 (20.1) 84 (12.2) < 0.001 < 0.001 0.624 0.003
Pulmonary tuberculosis 124 (7.4) 21 (6.7) 109 (15.9) < 0.001 0.999 < 0.001 < 0.001
Asthma 20 (1.2) 15 (4.8) 65 (9.5) < 0.001 < 0.001 < 0.001 0.024
Lung function test
FVC % predicted 92.96 ± 10.02 72.55 ± 9.45 88.51 ± 15.02 < 0.001 < 0.001 < 0.001 < 0.001
FEV1% predicted 94.66 ± 9.14 72.8 ± 6.72 74.18 ± 16.57 < 0.001 < 0.001 < 0.001 0.035
FEV1/FVC 0.79 ± 0.05 0.77 ± 0.06 0.61 ± 0.09 < 0.001 < 0.001 < 0.001 0.006
Respiratory symptoms, n (%)
Cough for more than 3 months 1 (0.1) 2 (0.6) 19 (2.8) < 0.001 0.047 < 0.001 0.091
Sputum for more than 3 months 4 (0.2) 2 (0.6) 18 (2.6) < 0.001 0.999 < 0.001 0.104
Dyspnea 10 (0.6) 3 (1.0) 31 (4.5) < 0.001 0.999 < 0.001 0.012
Wheezing 116 (7.0) 37 (11.8) 154 (22.4) < 0.001 0.009 < 0.001 < 0.001
Chronic bronchitis 4 (0.2) 2 (0.6) 21 (3.1) < 0.001 0.717 < 0.001 0.054
Total 1666 313 687
Data are presented as mean ± standard deviation or number (percentage)
* P-value for comparison between normal and PRISm group; + P-value for comparison between normal and unrevealed COPD group; ‡ P-value for comparison
between PRISm and unrevealed COPD group
PRISm preserved ratio impaired spirometry, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume for 1 s, FVC forced vital capacity
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that in the unrevealed COPD group (750.71 ± 3216.02
USD; P = 0.041) was larger than that in the PRISm group
(Table 2).
Comparison of baseline characteristics, medical
utilization, and costs between subjects with and without
medically diagnosed COPD
Among the 2666 subjects, 131 patients (4.9%) were medic-
ally diagnosed with COPD during the 3 years’ follow-up.
Subjects with medically diagnosed COPD were older and
shorter, weighed less, had a heavier smoking history, and
more often had a history of pulmonary tuberculosis and
asthma than the remaining patients. Although data are
not shown, other co-morbidity was not significantly differ-
ent between groups. Subjects with medically diagnosed
COPD had more markedly impaired lung function and se-
vere symptoms than subjects without medically diagnosed
COPD. They also more frequently visited hospitals, more
frequently used COPD medication, and had greater
hospitalization cost than subjects without medically diag-
nosed COPD (Table 3).
Significant factors for COPD diagnosis in subjects overall
Multivariate analysis of all subjects showed that the possi-
bility of COPD diagnosis was increased to 10.0% with every
year’s increase in age (odds ratio [OR], 1.10; 95% confidence
interval [CI], 1.07–1.13; P < 0.001). A 1% increase in FVC
and FEV1 was significantly associated with a 3% increase
and 5% decrease in COPD diagnosis, respectively (FVC
[OR, 1.03; 95% CI, 1.01–1.05; P = 0.006] and predicted
FEV1 [OR, 0.95; 95% CI, 0.93–0.96; P < 0.001]). Dyspnea
(OR, 3.73; 95% CI, 1.23–7.68; P = 0.017), and wheezing
(OR, 2.90; 95%CI, 1.76–4.78; P < 0.001) were significant
predictive factors of a COPD diagnosis (Table 4).
Comparison of baseline characteristics, medical
utilization, and costs between PRISm patients with and
without medically diagnosed COPD
Among the 316 subjects with PRISm, 16 patients were
medically diagnosed with COPD during the 3-year
follow-up period. Subjects with medically diagnosed COPD
were older, shorter, weighed less, more often had asthma
and decreased FVC, and more frequently had dyspnea and
wheezing. Due to frequent hospital and medical utilization,
their hospitalization cost was greater than that of subjects
without medically diagnosed COPD (Table 5).
Significant factors for COPD diagnosis in PRISm
In multivariate analysis of subjects with PRISm, the possi-
bility of COPD diagnosis was increased to 14.0% for every
year that subjects aged (OR, 1.14; 95% CI, 1.05–1.24; P =
0.002). Wheezing (OR, 4.56; 95% CI, 1.08–19.35; P =
0.040) was a significant factor for a diagnosis of COPD in
PRISm patients (Table 6).
Table 2 COPD incidence, medication and hospital utilization, and cost
Normal PRISm Unrevealed COPD P-value P-value* P-value+ P-value‡
COPD incidence (/1000PY) 4.4 17.0 45.1 < 0.001 < 0.001 < 0.001 < 0.001
OPD visit, n (%) 51 (3.1) 22 (7.0) 131 (19.1) < 0.001 0.002 < 0.001 < 0.001
No. of OPD visit 0.10 ± 0.91 0.48 ± 2.96 1.86 ± 6.37 < 0.001 0.243 < 0.001 < 0.001
Hospitalization, n (%) 79 (4.7) 29 (9.3) 83 (12.1) < 0.001 0.004 < 0.001 0.571
ER visit, n (%) 23 (1.4) 12 (3.8) 36 (5.2) < 0.001 0.008 < 0.001 0.999
ICU admission, n (%) 12 (0.7) 6 (1.9) 19 (2.8) < 0.001 0.122 < 0.001 0.999
Total hospital visit, n (%) 121 (7.3) 41 (13.1) 169 (24.6) < 0.001 0.002 < 0.001 < 0.001
ICS, n (%) 4 (0.2) 5 (1.6) 20 (2.9) < 0.001 0.003 < 0.001 0.651
ICS + LABA, n (%) 2 (0.1) 11 (3.5) 50 (7.3) < 0.001 < 0.001 < 0.001 0.063
LAMA, n (%) – 4 (1.3) 44 (6.4) – – – < 0.001
SAMA, n (%) 12 (0.7) 12 (3.8) 36 (5.2) < 0.001 < 0.001 < 0.001 0.999
SABA, n (%) 14 (0.8) 11 (3.5) 54 (7.9) < 0.001 < 0.001 < 0.001 0.029
Systemic bronchodilator, n (%) 28 (1.7) 11 (3.5) 72 (10.5) < 0.001 0.094 < 0.001 < 0.001
Methylxanthine, n (%) 33 (2.0) 17 (5.4) 101 (14.7) < 0.001 0.001 < 0.001 < 0.001
Total prescribed medication, n (%) 57 (3.4) 26 (8.3) 127 (18.5) < 0.001 < 0.001 < 0.001 < 0.001
Hospitalization medical Cost (for 3 years) (USD) 186.17 ± 1411.24 398.61 ± 1975.51 750.71 ± 3216.02 < 0.001 0.297 < 0.001 0.041
Data are presented as mean ± standard deviation or number (percentage)
* P-value for comparison between the normal and PRISm group; + P-value for comparison between normal and unrevealed COPD group; ‡ P-value for comparison
between PRISm and unrevealed COPD group
PRISm preserved ratio impaired spirometry, COPD chronic obstructive pulmonary disease, PY person-year, OPD outpatient department, ER emergency room, ICU
intensive care unit, ICS inhaled corticosteroid, LABA long-acting beta-2 agonist, LAMA long-acting muscarine antagonist, SAMA short-acting muscarine antagonist,
SABA short-acting beta-2 agonist
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Discussion
We investigated the incidence of COPD in PRISm patients
and sought to identify significant risk factors of COPD in
PRISm patients. We found that PRISm patients were 4
times more likely to receive a COPD diagnosis than a
normal group. Sood et al. have also reported a high COPD
incidence in PRISm patients (about double that in the
normal population) [24]. We also showed that PRISm
patients paid more hospital visits, used more prescribed
COPD medications, and accounted for an increased
Table 3 Comparison of baseline characteristics, medical utilization, and costs between subjects with and without medically
diagnosed COPD
Subjects with medically diagnosed COPD Subjects without medically diagnosed COPD P-value
Age 68.58 ± 7.77 56.70 ± 11.00 < 0.001
Male, n (%) 123 (93.9) 2377 (93.8) 0.954
Height (cm) 164.04 ± 6.25 166.94 ± 6.86 < 0.001
Weight (kg) 60.35 ± 9.89 67.5 ± 10.2 < 0.001
Smoking history
Current smoking, n (%) 67 (51.2) 1351 (53.3) 0.631
Pack-years 41.1 ± 23.69 30.7 ± 18.52 < 0.001
Co-morbidity, n (%)
Pulmonary tuberculosis 28 (21.4) 226 (8.9) < 0.001
Asthma 3 (26.0) 66 (2.6) < 0.001
Lung function test
FVC % predicted 81.14 ± 15.77 89.85 ± 12.85 < 0.001
FEV1% predicted 66.37 ± 19.36 87.87 ± 14.17 < 0.001
FEV1/FVC 0.59 ± 0.16 0.75 ± 0.09 < 0.001
Respiratory symptoms, n (%)
Cough for more than 3 months 14 (10.7) 8 (0.3) < 0.001
Sputum for more than 3 months 11 (8.4) 13 (0.5) < 0.001
Dyspnea 23 (17.6) 21 (0.8) < 0.001
Wheezing 60 (45.8) 247 (9.7) < 0.001
Chronic bronchitis 14 (10.7) 13 (0.5) < 0.001
OPD visit, n (%) 116 (88.6) 88 (3.5) < 0.001
No. of OPD visit 10.88 ± 11.77 0.07 ± 0.59 < 0.001
Hospitalization, n (%) 67 (51.2) 124 (4.9) < 0.001
ER visit, n (%) 35 (26.7) 36 (1.4) < 0.001
ICU admission, n (%) 17 (13.0) 20 (0.8) < 0.001
Total hospital visit, n (%) 131 (100) 200 (7.9)
ICS, n (%) 25 (19.1) 4 (0.2) < 0.001
ICS + LABA, n (%) 54 (41.2) 9 (0.4) < 0.001
LAMA, n (%) 42 (32.1) 6 (0.2) < 0.001
SAMA, n (%) 44 (33.6) 16 (0.6) < 0.001
SABA, n (%) 60 (45.8) 19 (0.8) < 0.001
Systemic bronchodilator, n (%) 75 (57.3) 36 (1.4) < 0.001
Methylxanthine, n (%) 110 (84.0) 41 (1.6) < 0.001
Total prescribed medication, n (%) 131 (100.0) 79 (3.1) –
Hospitalization medical Cost (for 3 years) (USD) 4041.23 ± 6633.39 166.17 ± 1286.46 < 0.001
Total 131 2535
Data are presented as mean ± standard deviation or number (percentage)
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume for 1 s, FVC forced vital capacity, OPD outpatient department, ER emergency room,
ICU intensive care unit, ICS inhaled corticosteroid, LABA long-acting beta-2 agonist, LAMA long-acting muscarine antagonist, SAMA short-acting muscarine
antagonist, SABA short-acting beta-2 agonist
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economic burden. Despite not meeting COPD criteria,
these patients require careful observation because of their
risk for COPD development and concomitant medical
utilization. PRISm occurs in about 6.6–17.6% of the
general global population [15, 25, 26]; nevertheless, PRISm
remains poorly understood. Many clinicians miss this
“unclassified” or “non-specific” group, and discharge them
without explanation, warning, or follow-up appointment.
Detecting and treating these early-stage patients is
requisite.
Some subjects with PRISm might have underlying re-
strictive lung disease. Significantly lower FVC (72.55 ±
9.45%) in PRISm patients than in normal (92.96 ± 10.02;
P < 0.001) and unrevealed COPD (88.51 ± 15.02; P <
0.001) subjects supports this supposition. However, Wan
et al. reported that a true restrictive pattern, defined by
total lung capacity, was not frequently observed in
PRISm [10]. This should be elucidated in further studies.
Subjects in the PRISm group had a heavier smoking
history, more severe respiratory symptoms and de-
creased lung function, and more frequent co-morbidity
than the normal population; these differences were less
marked when compared to the unrevealed COPD group.
However, we found that the prevalence of current smok-
ing in the PRISm group was higher than that in both the
normal and unrevealed COPD groups. It may be that
many current-smokers in the PRISm group did not ex-
perience respiratory symptoms, did not visit hospitals,
and were not warned to stop smoking. Current-smokers
in the PRISm group may develop COPD unless they stop
smoking, as previously shown [24]. Doctors should
check the smoking status in PRISm patients more care-
fully, and should strongly recommend that they stop
smoking.
Although age, lung function, dyspnea, and wheezing
are significant predictive factors of COPD in the subjects
overall, only age and wheezing were significant predict-
ive factors for a COPD diagnosis in PRISm patients.
Both age [27] and wheezing [28] are well-known predict-
ive factors for COPD.
Lung function was not a significant predictive factor of
COPD in PRISm. Low FEV1 was a significant predictive
factor of COPD overall, but not in PRISm patients spe-
cifically. The preserved ratio which is shown in PRISm
means that these patients rarely have an extremely re-
duced FEV1. In fact, Table 1 shows a relatively small
standard deviation of FEV1 in PRISm patients, as com-
pared to other groups, although the number of subjects
was small. It implies FEV1 in PRISm has small predictive
power for prognosis. Thus, it is necessary to monitor
Table 4 Significant factors for COPD diagnosis in all subjects
Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age (years) 1.11 (1.09,1.13) < 0.001 1.10 (1.07,1.13) < 0.001
Male 1.02 (0.49,2.13) 0.954
Height (cm) 0.95 (0.92,0.97) < 0.001 1.01 (0.97,1.05) 0.786
Weight (kg) 0.93 (0.91,0.95) < 0.001 0.98 (0.95,1.01) 0.143
Smoking history
Current smoking 0.92 (0.65,1.3) 0.631
Pack-years 1.02 (1.01,1.03) < 0.001 1.01 (1.00,1.02) 0.059
Co-morbidity
Pulmonary tuberculosis 2.78 (1.79,4.31) < 0.001 1.17 (0.66,2.10) 0.587
Asthma 13.11 (8.27,20.79) < 0.001 1.88 (0.97,3.64) 0.060
Lung function test
FVC % predicted 0.95 (0.94,0.97) < 0.001 1.03 (1.01,1.05) 0.006
FEV1% predicted 0.93 (0.92,0.94) < 0.001 0.95 (0.93,0.96) < 0.001
FEV1/FVC 0.001 (0.001,0.001) < 0.001
Self-reported respiratory symptoms
Cough for more than 3 months 37.80 (15.55,91.87) < 0.001 2.40 (0.24,24.32) 0.458
Sputum for more than 3 months 17.78 (7.81,40.52) < 0.001 0.48 (0.02,10.90) 0.647
Dyspnea 25.49 (13.68,47.49) < 0.001 3.07 (1.23,7.68) 0.017
Wheezing 7.83 (5.42,11.31) < 0.001 2.90 (1.76,4.78) < 0.001
Chronic bronchitis 23.21 (10.67,50.5) < 0.001 2.76 (0.07,109.05) 0.588
Statistically significant data are presented as bold
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume for 1 s, FVC forced vital capacity, OR odds ratio, CI confidence interval
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PRISm subjects carefully, even in the absence of severe
reduced FEV1.
Additionally, relatively preserved FVC was a significant
predictive factor for COPD in the overall cohort using
multivariate analysis, but not in PRISm patients. The
reasons why preserved FVC is significant risk factor for
COPD are as follows. Before adjustment, FVC in sub-
jects with medically diagnosed COPD (81.14 ± 15.77%)
was significantly lower than that in subjects without
COPD (89.85 ± 12.85%; P < 0.001). We can easily assume
Table 5 Comparison of baseline characteristics, medical utilization, and costs between PRISm with and without medically diagnosed
COPD
PRISm with medically diagnosed COPD PRISm without medically diagnosed COPD P-value
Age 70.06 ± 7.48 55.21 ± 10.49 < 0.001
Male, n (%) 16 (100.0) 270 (90.9) –
Height (cm) 162.95 ± 6.9 167.0 ± 6.89 0.023
Weight (kg) 61.58 ± 13.13 69.04 ± 11.41 0.012
Smoking history
Current smoking, n (%) 8 (50.0) 185 (62.3) 0.325
Pack-years 36.63 ± 14.16 33.02 ± 20.62 0.490
Co-morbidity, n (%)
Pulmonary tuberculosis 1 (6.3) 20 (6.7) 0.940
Asthma 4 (25.0) 11 (3.7) < 0.001
Lung function test
FVC % predicted 64.83 ± 10.86 72.96 ± 9.2 < 0.001
FEV1% predicted 69.77 ± 9.16 72.97 ± 6.55 0.188
FEV1/FVC 0.76 ± 0.06 0.77 ± 0.06 0.182
Respiratory symptoms, n (%)
Cough for more than 3 months 0 2 (0.7) –
Sputum for more than 3 months 0 2 (0.7) –
Dyspnea 2 (12.5) 1 (0.3) < 0.001
Wheezing 6 (37.5) 31 (10.4) 0.001
Chronic bronchitis 0 2 (0.7) –
OPD visit, n (%) 15 (93.8) 7 (2.4) < 0.001
No. of OPD visit 8.81 ± 10.15 0.03 ± 0.18 < 0.001
Hospitalization, n (%) 9 (56.3) 20 (6.7) < 0.001
ER visit, n (%) 5 (31.3) 7 (2.4) < 0.001
ICU admission, n (%) 2 (12.5) 4 (1.4) 0.002
Total hospital visit, n (%) 16 (100.0) 25 (8.4) –
ICS, n (%) 4 (25.0) 1 (0.3) < 0.001
ICS + LABA, n (%) 8 (50.0) 3 (1.0) < 0.001
LAMA, n (%) 4 (25.0) – –
SAMA, n (%) 8 (50.0) 4 (1.4) < 0.001
SABA, n (%) 8 (50.0) 3 (1.0) < 0.001
Systemic bronchodilator, n (%) 9 (56.3) 2 (0.7) < 0.001
Methylxanthine, n (%) 11 (68.8) 6 (2.0) < 0.001
Total prescribed medication, n (%) 16 (100.0) 10 (3.4) –
Hospitalization medical Cost (for 3 years) (USD) 3647.51 ± 4773.55 223.58 ± 1535.45 0.012
Total 16 297
Data are presented as mean ± standard deviation or number (percentage)
PRISm preserved ratio impaired spirometry, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume for 1 s, FVC forced vital capacity, OPD
outpatient department, ER emergency room, ICU intensive care unit, ICS inhaled corticosteroid, LABA long-acting beta-2 agonist, LAMA long-acting muscarine
antagonist, SAMA short-acting muscarine antagonist, SABA short-acting beta-2 agonist
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that preserved FVC will be protective factor for COPD,
however results were contrary to that in multivariate
analysis with adjustment. This indicates that other asso-
ciated co-variables affected the findings of FVC in multi-
variate analysis. We speculated FEV1 might be
contributing factor for this confusing result. The decline
in FEV1 was much larger than that in FVC in Table 3,
and FVC is unavoidably influenced by changes in FEV1.
Therefore, we speculated that FEV1, as a co-variable,
might have affected the FVC findings in multivariate
analysis with adjustment.
Unrevealed COPD implies a significantly impaired
FEV1/FVC ratio, meeting the standard COPD spirometry
criteria for airway obstruction, but without a clinical
diagnosis of COPD, no hospital visits, and no use of
COPD medication to date. The number of subjects with
unrevealed COPD was double that of the PRISm group
in this study. Coultas et al. showed a similar proportion
of undiagnosed COPD (79.7%) in the USA [3]. Chung et
al. have shown that, in Korea, 97% of COPD cases are
undiagnosed [2], or misdiagnosed [29]; their diagnosis
and treatment should be addressed, because unrevealed
COPD also leads to more hospital visits, increased medi-
cation use, and an increased economic burden [30].
Woodruff et al. showed that smokers with normal lung
function commonly experience respiratory symptoms and
exacerbations. They suggested a new entity that includes
smoking-related chronic pulmonary disease [6]. Other re-
cent studies also suggest that the pre-COPD stage is clin-
ically and medically important [31, 32]. We assume that
PRISm may also be a pre-COPD-stage chronic pulmonary
disease. PRISm patients should be advised to have regular
check-ups to monitor COPD development, and more so if
they have advance aged or wheezing, irrespective of the
severity of lung function decrease (FEV1).
This study had some limitations. First, “medically diag-
nosed COPD” may be considered artificial. “COPD inci-
dence” is not an accurate term, but in this study reflects
the incidence of medically diagnosed COPD as defined by
the HIRA data, which includes insurance claims but not
pulmonary function test data. However, the previously re-
ported COPD incidence (2.6–9.2/1000 PY) [27, 33–35] is
not markedly different from that in this study (4.4/1000
PY in normal; 17.0/1000 PY in PRISm). “Medically diag-
nosed COPD” with hospital visits and medication use is
more relevant than COPD diagnosed based only on im-
paired lung function (FEV1/FVC < 0.7), without medical
utilization. Therefore, this artificial definition may be
Table 6 Significant factors for COPD diagnosis in PRISm
Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age (years) 1.14 (1.08, 1.21) < 0.001 1.14 (1.05, 1.24) 0.002
Male
Height (cm) 0.93 (0.87, 0.99) 0.025 1.03 (0.92, 1.16) 0.564
Weight (kg) 0.94 (0.9, 0.99) 0.013 0.95 (0.89, 1.02) 0.153
Smoking history
Current smoking 0.61 (0.22, 1.66) 0.329
Pack-years 1.01 (0.99, 1.03) 0.490
Co-morbidity
Pulmonary tuberculosis 0.92 (0.12, 7.35) 0.940
Asthma 8.67 (2.41, 31.23) 0.001 5.87 (0.94, 36.56) 0.058
Lung function test
FVC % predicted 0.93 (0.89, 0.97) 0.001 1.01 (0.95, 1.09) 0.694
FEV1% predicted 0.95 (0.9, 1.01) 0.071
FEV1/FVC 0.001 (0.001, 35.7) 0.183
Self-reported respiratory symptoms
Cough for more than 3 months
Sputum for more than 3 months
Dyspnea 42.29 (3.61, 494.74) 0.003 8.88 (0.65, 121.7) 0.102
Wheezing 5.15 (1.75, 15.14) 0.003 4.56 (1.08, 19.35) 0.040
Chronic bronchitis
Statistically significant data are presented as bold
COPD chronic obstructive pulmonary disease, PRISm preserved ratio impaired spirometry, FEV1 forced expiratory volume for 1 s, FVC forced vital capacity, OR odds
ratio, CI confidence interval
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appropriate for use in this study. Second, this cohort study
did not include follow-up pulmonary function tests, be-
cause the KNHANES conducted pulmonary function tests
in different populations each year.
Conclusions
PRISm is likely to develop into COPD over time, and it
leads to frequent hospital visits, increased medication
use, and greater hospitalization costs. Subjects with
PRISm should be carefully monitored for COPD devel-
opment, especially when they are older or have wheez-
ing, regardless of lung function.
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